Lisata Therapeutics, Inc. has filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation to implement a one-for-fifteen reverse stock split of its common stock. The amendment was filed with the Secretary of State of Delaware on November 19, 2026.

The reverse stock split is scheduled to become effective at 12:01 a.m., Eastern Time, on November 23, 2026. As a result of the split, every fifteen shares of Common Stock issued and outstanding immediately before the Effective Time will be combined into one share of Common Stock. The par value per share remains at $0.001, and the total number of authorized shares of Common Stock remains unchanged.

According to the filing, the number of issued and outstanding shares of common stock will be reduced from approximately 10.8 million shares to approximately 0.7 million shares. The reverse stock split will not affect any stockholder’s percentage ownership interest in the Company, except for minor changes that may result from the treatment of fractional shares.

No fractional shares will be issued in connection with the split. Stockholders who would otherwise be entitled to a fractional share will receive a cash payment equal to the fractional share interest multiplied by the closing price of the Common Stock on The Nasdaq Capital Market on November 19, 2026.

Trading of the Common Stock on The Nasdaq Capital Market will commence on a split-adjusted basis at the market open on November 23, 2026, under the existing trading symbol “LSTA.” The new CUSIP number for the Company’s Common Stock following the reverse stock split is 128058 401.